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Several lines of evidence support the impor-
tance of CD8+ T cells in limiting HSV reac-
tivation from latently infected ganglia and in 
controlling lytic mucocutaneous infection. 
  Patients with iatrogenic immune suppression 
and hereditary or acquired immunodefi  ciency 
experience both more frequent reactivation 
and prolonged symptomatic episodes of in-
fection (1–3). In mice, HSV-1–specifi  c T cells 
have been demonstrated in latently infected 
neural ganglia, and depletion or neutralization 
of these cells from the ganglionic neural tis-
sue is associated with reactivation of virus from 
neural tissue in an ex vivo explant model (4, 5). 
In humans, CD8+ T cells have been shown to 
infi  ltrate genital lesions, and the clearance of 
HSV-2 from genital herpes lesions is associated 
with the infl  ux of HSV-specifi  c CD8+ T cells 
(6–9). However, little is known of the spatial 
distribution of HSV-specifi  c T cells with respect 
to HSV-infected cells, their persistence after le-
sion resolution, and the relative importance of 
host immunity in the ganglion versus peripheral 
mucosal areas in containing viral reactivation.
In situ staining of pathogen-specifi  c CD8+ 
T cells has been demonstrated using antigen-
specifi  c tetramers (10, 11). This technology has 
been used to evaluate compartmentalized im-
mune responses to a variety of infections that 
stimulate high frequencies of pathogen-specifi  c 
T cells (12, 13). HSV infections of humans off  er 
challenges for such technology, as the frequency 
of total HSV-specifi  c CD8+ T cell responses in 
PBMCs are much lower than in HIV or EBV 
infection (14–16), and human skin has much 
higher autofl  uorescence than lymphoid tissue 
(17–19). Quantum dots (Qdots) are fl  uorescent 
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Cytotoxic CD8+ T cells play a critical role in controlling herpes simplex virus (HSV) infec-
tion and reactivation. However, little is known about the spatiotemporal dynamics of CD8+ 
T cells during HSV lesion evolution or about their involvement in immune surveillance after 
lesion resolution. Using quantum dot–conjugated peptide–major histocompatibility complex 
multimers, we investigated the in vivo localization of HSV-2–specifi  c CD8+ T cells in 
  sequential biopsies of human genital skin during acute, resolving, and healed stages of 
HSV-2 reactivation. Our studies revealed that functionally active CD8+ T cells selectively 
infi  ltrated to the site of viral reactivation. After lesion healing in concert with complete 
reepithelialization and loss of HSV DNA from skin biopsies, HSV-2–specifi  c CD8+ T cells 
persisted for more than two months at the dermal–epidermal junction, adjacent to periph-
eral nerve endings. In two out of the six sequentially studied individuals, HSV-2 DNA 
reappeared in clinically and histologically normal–appearing skin. Detection of viral DNA 
was accompanied by increased numbers of both HSV-specifi  c and total CD8+ T cells in the 
dermis. These fi  ndings indicate that the frequency and clinical course of HSV-2 reactivation 
in humans is infl  uenced by virus-specifi  c CD8+ T cells that persist in peripheral mucosa 
and genital skin after resolution of herpes lesions.
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nanoscaled crystalline probes that off  er several advantages for 
cellular labeling and imaging (20–22). In this study, we de-
scribe the synthesis of Qdot-conjugated peptide–MHC mul-
timers (Qdot multimers), which provide higher sensitivity 
and photostability than conventional tetramers (23). We used 
these reagents to demonstrate the in vivo persistence of HSV-2–
specifi  c CD8+ T cells in genital skin after disease resolution, 
their location contiguous to peripheral nerve endings at the 
dermal–epidermal junction, and their role in containing the 
formation of lesions caused by reactivated virus. Our data 
suggest that for HSV-2, containment by virus-specifi  c CD8+ 
T cells in the periphery appears to be an important, if not 
the predominant, means by which the host limits HSV-2 at 
mucosal surfaces.
RESULTS
To study the spatiotemporal distribution of HSV-2–specifi  c 
CD8+ T cells during the evolution of HSV-2 reactivation, 
serial 3-mm punch biopsies from six HSV-2 seropositive, 
HIV seronegative subjects with recurrent genital herpes were 
obtained. Patients were selected from a cohort of persons 
who participated in prior studies and who had defi  ned CD8+ 
T cell responses to HSV-2 (8,14). Patients underwent from 
two to seven separate biopsies over the course of study (Table I). 
Qdot multimers recognizing peptide epitopes encoded by 
HSV-2 UL26, UL27, UL46, UL47, and UL49 genes were 
synthesized, and in situ staining for HSV-2–specifi  c CD8+ 
T cells was conducted.
CD8 cytolytic activity at the site of herpes recurrence
During the acute phase of genital recurrence, productive 
HSV-2 viral replication was associated with disruption of 
the epidermal layer (Fig. 1 a). Immune cell infi  ltration was 
massive at the site of infection and diff  ered markedly from 
that observed in biopsies taken at the same time from distant 
skin sites (Fig. 1 a). CD8+ T cells were detected both below 
and within the HSV-2–infected epidermis (Video 1, available 
at http://www.jem.org/cgi/content/full/jem.20061792/DC1); 
three-dimensional modeling constructed from confocal 
images of the late ulcer/early crust stage (Fig. 1 b) revealed 
cell-to-cell interactions between CD8+ T lymphocytes and 
the HSV-2–infected epidermal keratinocytes. The presence 
of multiple junctions between CD8+ T cells and HSV-2–
  infected keratinocytes is consistent with the formation of 
immunological synapses between antigen-specifi  c CD8+ T 
cells and their targets in vivo (Video 2). To demonstrate the 
functional competence of these CD8+ T cells, lymphocytes 
were recovered from recurrent genital lesions biopsied at the 
time of HSV-2 culture conversion from positive to negative. 
The lymphocytes were expanded and examined for cyto-
lytic function by chromium release assays, as previously de-
scribed (9). CD4+ CD8− and CD4− CD8+ T lymphocytes 
and CD3− CD56+ NK cells were the three main subpopu-
lations detected after expansion (Fig. 1 c). HLA class I–re-
stricted, HSV-2 antigen–specifi  c cytolytic activity of CD8+ 
T cells was clearly present both at bulk culture and selected T 
cell levels (Fig. 1 c), indicating that CD8+ cytolytic T lym-
phocytes specifi  c for HSV-2 contribute to the resolution of 
lesions in patients with genital herpes.
Qdot multimers
Based on previous work defi  ning the HSV-2–specifi  c epi-
topes and immunodominant responses restricted by HLA 
A*0101, A*0201, and B*0702 alleles (8, 24), peptides en-
coded by the HSV-2 UL26, UL27, UL46, UL47, and UL49 
genes were used to synthesize Qdot 655–conjugated multi-
mers (see Materials and methods). Qdot 655 conjugates 
were constructed to average between seven and eight strep-
tavidin molecules covalently attached to each Qdot particle, 
thus binding up to 32 peptide–MHC monomers under satu-
rated condition (Fig. 2 a). The photostability of the Qdot 
multimer allowed high quality confocal laser scanning, in-
cluding detailed imaging of TCR molecules on the cell sur-
face (Fig. 2 b and Video 3, available at http://www.jem
.org/cgi/content/full/jem.20061792/DC1). The Qdot 655 
multimers exhibited similar specifi  city but had higher signal 
Table I.  Clinical history of genital herpes and time of genital lesion biopsies studied
Subjects P1 P2 P3 P4 P5 P6
HSV serology 1 and 2 2 1 and 2 1 and 2 1 and 2 2
Age/gender 46/female 58/male 44/female 54/female 42/female 41/female
No. years with HSV-2 28 25 18 16 22 20
Lesion site labia buttock buttock buttock perianal buttock
Stage of genital 
lesion at time 
of biopsy
ulcer 
crust 
healed 
2 wk p.h. 
4 wk p.h. 
6 wk p.h. 
8 wk p.h.
pustule 
crust 
2 wk p.h. 
4 wk p.h. 
6 wk p.h. 
8 wk p.h.
pustule 
crust 
2 wk p.h. 
4 wk p.h. 
8 wk p.h.
crust 
2 wk p.h. 
6 wk p.h.
ulcer 
2 wk p.h. 
6 wk p.h.
crust 
4 wk p.h.
HLA type A01, 26; 
B07, 08
A01, 02; 
B08, 45
A11, 29; 
B07, 41
A02, 23; 
B49, 60
A68; 
B35, 44
A01, 02; 
B08, 57
p.h., post-healing of the lesion (skin epithelialized).JEM VOL. 204, March 19, 2007  597
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intensity and better sensitivity than PE- (Fig. 2 c) or allo-
phycocyanin-labeled (not depicted) tetramers bearing the 
same peptide.
Site-specifi  c infi  ltration of HSV-2–specifi  c CD8+ T cells 
in recurrent genital lesions
We fi  rst quantitated the number of total CD8+ cells in the 
lesional area during the acute stage of the herpetic lesion. In-
fi  ltrating CD8+ cells averaged 1,504 ± 337 cells/mm2 in a 
10-μm thick tissue (n = 6). Genital skin biopsies from 2 to 5 
cm away (n = 4) revealed a dramatically decreased density of 
CD8+ cell infi  ltration (mean = 60 ± 48 cells/mm2), and skin 
biopsies of the arm region (n = 4) collected at the same time 
as the lesional biopsies averaged 12 ± 6 cells/mm2 (Fig. 3 a). 
In addition, 30–50% of the CD8+ cells detected in both the 
distal arm area and neighboring genital skin were located 
within blood vessels, not in extravascular tissue. Thus, the 
CD8+ cell infi  ltration into dermal and epidermal skin tissue 
in persons with genital herpes lesions was limited spatially to 
the site of viral infection.
We then stained HSV-2–specifi  c CD8+ T cells in situ by 
the Qdot 655–conjugated multimers during the acute lesional 
stage. In four out of the fi  ve patients tested, HSV-2–specifi  c 
CD8+ T cells were detected in the epidermis, dermis, and 
dermal–epidermal junction of active lesions (Fig. 3 b) and 
were not visualized in either biopsies of distant skin or from 
areas 2–5 cm away from the active lesions. HSV-2–specifi  c 
CD8+ T cells were not seen if Qdot multimers containing 
Figure 1.  Spatial and functional CD8+ CTL activity during an 
acute genital herpetic lesion. (a) Hematoxylin and eosin staining 
of normal arm (left) and lesional skin (middle). Immunofl  uorescence 
staining (right) for CD8+ cells (green) and HSV-2–infected cells (red). 
(b) Confocal image of CD8+ and HSV-2–infected cells in an acute lesion. 
Montages of a CD8+ cell (green) in proximity to HSV-2–infected cells 
(blue) were displayed at 1-μm intervals (left). (middle and right) The 0° 
(front) and 180° (back) views of a three-dimensional rendering of the 
interactions. (c) HSV-2–specifi  c CD8 cytolytic activity as measured by 
chromium release in lymphocytes cultured from a lesion biopsy 5 d after 
onset, using either bulk or CD8-enriched cultured cells as effectors, 
and either the autologous or HLA-mismatched B lymphocyte blasts 
uninfected or HSV-2 infected as targets. Effector/target cell ratio = 20:1. 
Bars: (a) 50 μm; (b) 10 μm.
Figure 2.  Qdot 655–conjugated peptide–MHC I multimer. (a) Sche-
matic representation of the structure of Qdot 655–conjugated peptide–MHC I 
multimer complexes as compared with standard tetramers. (b) HSV-specifi  c 
CD8+ T cells stained with an anti-CD8 antibody (green) and Qdot 655 mul-
timer (red) for TCR recognizing the B*0702-restricted HSV-2 peptide gene 
UL49 (aa 49–57). A maximum projection displays surface distributions of 
CD8 and TCR molecules on the double-positive cell (right). Stacks of confo-
cal images were taken with a 100× objective at 0.2-μm intervals. (c) Detec-
tion of HSV-2–specifi  c CD8+ T cells by fl  ow cytometry using PE-labeled 
tetramer and Qdot 655–conjugated multimer. Peptide-stimulated (HSV-2 
gene UL46, aa 354–362) PBMC from subject P1 was incubated either with 
A*0101/ASD-PE (left) or with A*0101/ASD–Qdot 655 (middle). Qdot multimer 
A*0101/ASD–Qdot 655 shows similar specifi  city but increased signal inten-
sity as compared with PE-labeled tetramer (right). Bar, 5 μm.598  PERSISTENCE OF HSV-SPECIFIC CD8 AGAINST GENITAL HERPES | Zhu et al.
HSV-2 peptide combinations HLA-mismatched to the do-
nor, or CMV pp65 peptide combinations HLA-matched to 
the donor, were used (Fig. 3 c). Additional specifi  city of the 
Qdot multimers for HSV-2 was demonstrated in subject P1, 
who developed a folliculitis in the genital skin during this 
study. Biopsy of the follicular lesion showed CD8+ T cell in-
fi  ltration (mean = 434 ± 24 cells/mm2) but no evidence of 
HSV-2–specifi  c CD8+ T cells (Fig. 3 c).
The frequency of CD8+ T cells specifi  c for the HLA 
B*0702–restricted epitope UL49 (aa 49–57) comprised  10% 
of all CD8+ cells in lesional tissue,  100 times the frequency 
that these cells were found in blood (0.1% of CD8+ cells). 
The enrichment of HSV-2–specifi  c CD8+ T cells in geni-
tal lesions was also seen in the two HLA A*0201–bearing 
subjects, where the frequency of detection was increased 
from undetectable in blood to 0.7 and 1.9% in tissues for 
subject P2 and P6, respectively (see Fig. 6 c). These data 
demonstrate that lesional CD8+ T cells recognizing HSV-2 
epitopes can be identifi  ed with a high degree of specifi  city 
using the Qdot multimer technique, that HSV-2–specifi  c 
CD8+ T cells home specifi  cally to HSV-infected skin le-
sions, and that the CD8+ T cell response to HSV-2 is highly 
focused anatomically.
Persistence of HSV-2–specifi  c CD8 T cells after 
lesion resolution
To study the potential persistence of HSV-2–specifi  c 
CD8+ T cells after resolution of a herpetic lesion, subjects 
underwent repeated biopsies of the genital skin at the time 
of healing and sequential time periods from 2 to 8 wk af-
ter lesion resolution (Table I). The epidermis was intact and 
appeared clinically normal when these biopsies were taken. 
In contrast to acute infection, where HSV-2–specifi  c CD8+ 
T cells could be detected in all skin layers (Fig. 3 b), CD8+ 
T cells in newly healed lesions were concentrated at the 
dermal–epidermal junction and in the upper dermis. HSV-2–
specifi  c CD8+ T cells were detected in small clusters in 
the upper dermis, in particular just beneath the basement 
membrane, and very few CD8+ cells infi  ltrated the epidermis 
(Video 4, available at http://www.jem.org/cgi/content/full/
jem.20061792/DC1).
Resolution of the genital lesion was associated with 
skin reepithelialization and loss of HSV by culture or DNA 
detection in lesional biopsy tissue. However, HSV-2–spe-
cifi  c  CD8+ T cells were consistently detected in healed 
genital skin along the dermal–epidermal junction. Most of 
the CD8+ T cells, including HSV-2–specifi  c CD8+ T cells, 
were in close contact to basal keratinocytes (Fig. 4, a–c; and 
Video 5, available at http://www.jem.org/cgi/content/full/
jem.20061792/DC1). This persistence of HSV-specific 
T cells at the dermal–epidermal junction in the lesional 
biopsies was documented in all of the postresolution 
  biopsies of all six subjects studied. HSV-2–specifi  c CD8+ 
T cells persisted at similar frequencies to those in acute in-
fection (see Fig. 6 c), suggesting that HSV-2–specifi  c CD8+ 
T cells remain locally enriched at the dermal–epidermal 
Figure 3.  HSV-2–specifi  c CD8+ T cell infi  ltration in recurrent herpes 
lesion. (a) Quantitation of CD8+ T cell infi  ltration in acute genital lesion 
compared with biopsies from adjacent normal genital skin or distal normal 
forearm skin. At least fi  ve fi  elds were counted for each biopsy. (b) Detection 
of HSV-2–specifi  c CD8+ T cells in the epidermis (left), dermis (middle), and 
at the dermal–epidermal junction (right) in lesional skin. Biopsies were 
stained with anti-CD8 antibody (green), a cocktail of Qdot multimers (red), 
and DAPI (blue). HSV-2–specifi  c CD8+ T cells appear in yellow. (c) Absence of 
antigen-specifi  c CD8+ T cells in herpes lesions from the same patient using 
HLA-mismatched (left, top) or antigen-mismatched (left, bottom) Qdot 
 multimers.  HSV-2–specifi  c CD8+ T cells were also absent in folliculitis (right, 
top) or in normal skin (right, bottom), also in the same subject. Bars, 20 μm.JEM VOL. 204, March 19, 2007  599
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junction even in the wake of a waning overall infl  amma-
tory response.
Spatial relationship of CD8+ T cells and cutaneous sensory 
nerve endings
Because HSV reactivates from cutaneous sensory nerve end-
ings, we postulated that HSV-2–specifi  c CD8+ T cells persist-
ing in healed genital herpes lesions would position themselves 
in close proximity to these nerves to optimally suppress reacti-
vation. To test this hypothesis, we analyzed the spatial relation-
ship between CD8+ T cells and peripheral nerve endings. To 
visualize the three-dimensional topography of the cutaneous 
nerve plexus, we prepared dermal sheets, stained them with 
a monoclonal antibody against neural cell adhesion molecule 
(NCAM), and performed confocal microscopy. Free-ending 
nerve fi  bers and enveloped terminal Schwann cells formed a 
distinct network throughout the entire superfi  cial dermis (Fig. 
5 a). Nearly all the terminal nerve endings spread out within a 
thin layer below the dermal–epidermal junction, whereas large 
nerve trunks were located deeper in the dermis. In normal 
unaff  ected skin, CD8+ cells were mainly detected in capillary 
blood vessels deep in the dermis and had no association with 
nerve-ending organs in the skin (Fig. 5 d and Fig. 3 c, normal 
skin). However, in posthealed lesional skin, many CD8+ 
T cells were found adjacent to basal cells of the epidermis that 
were contacted by free nerve endings and adjacent to termi-
nal Schwann cells (Fig. 5, b and c; and Video 6, available at 
http://www.jem.org/cgi/content/full/jem.20061792/DC1). 
We also documented CD8+ T cells with HSV-2 specifi  city 
at these sites (Fig. 5 b). These fi  ndings showed that persisting 
CD8+ T cells associate with sensory cutaneous nerve endings 
after lesion healing, often in the vicinity of basal keratinocytes, 
the primary infected cell type during reactivation of HSV. 
This spatial relationship suggests that HSV-specifi  c CD8+ 
T cells may control HSV reactivation peripherally by posi-
tioning themselves as sentinels at the interface between reacti-
vating nerve endings and adjacent basal keratinocytes.
Relationship between HSV-2 detection in tissue and number 
and location of HSV-specifi  c CD8+ T cells
To investigate the temporal relationship between HSV-2 
infection and CD8+ T cell infi  ltration during and after geni-
tal herpes episodes, we subjected serial biopsies to viral DNA 
detection and CD8+ T cell quantifi  cation. All 10 biopsies 
taken during acute lesions were both culture and PCR posi-
tive for HSV at the time of collection. For HSV-2 DNA, ge-
nome copies ranged from 2.2 × 103 to 5.4 × 106 per 50,000 
cells (Fig. 6 a). HSV-2 DNA, as detected by PCR from tissue 
sections, rapidly decreased after healing (Fig. 6 a). Similarly, 
a rapid decrease in the number of CD8+ T cells occurred dur-
ing the course of healing (Fig. 6 b). All 31 biopsies done after 
reepithelialization, including 24 taken from the original le-
sion site and 7 taken from unaff  ected normal areas (4 adjacent 
to and 3 distal from the lesion), were cultured negative for 
HSV. 20 out of these 24 posthealing biopsies taken from the 
original lesion site and all 7 biopsies taken from unaff  ected 
sites were also negative for HSV-2 DNA.
Four posthealing lesional biopsies from two separate sub-
jects demonstrated reappearance of HSV-2 DNA. Subject P2 
had HSV-2 DNA detected in the 2-wk and the 8-wk 
posthealing biopsies (21 and 19 copies of HSV-2 DNA per 
50,000 cells, respectively). No HSV-2 DNA was detected 
in the biopsies that preceded and followed the 8-wk biopsy. 
A similar pattern was seen in subject P3, who had HSV 
DNA detected at the 4-wk and 8-wk posthealing tissues 
(2 and 15 copies of HSV-2 DNA per 50,000 cells, respectively). 
Histologic sections of these skin biopsies showed an intact 
epithelium in all four of these biopsies; with no clinical or 
histologic evidence of ulceration or epidermal break (Fig. 6, d 
and e), as such, the HSV-2 shed into tissue was “subclinical” 
by defi  nition.
Increased numbers of both HSV-2–specifi   c and total 
CD8+ T cells were detected in the posthealing biopsies in 
which HSV-2 DNA was present (Fig. 6, b–e). For example, 
the number of total CD8+ T cells detected in the 8-wk 
Figure 4.  HSV-2–specifi  c CD8+ T cells persist at the dermal–
  epidermal junction after the lesion heals and reepithelializes. (a) Cross-
sectional view of a biopsy taken 4 wk after healing. DAPI stain (blue) 
illustrates normal epidermal layer. CD8+ T cells are found at the junction 
of the epidermis and dermis, and very few cells are located in the epider-
mis or in deep dermal areas. (b) Detection of HSV-2–specifi  c CD8+ T cells 
(yellow) at the dermal–epidermal junction in a biopsy taken 4 wk after 
healing. Tissue was stained with a cocktail of B*0702 UL49/RPR and UL26/
GPH multimers (red) and anti-CD8 antibody (green). HSV-2–specifi  c CD8+ 
T cells appear in yellow. (c) A horizontal view demonstrates CD8+ T cells in 
close contact with the basal cells at the basement membrane. The tissue 
was obtained from a skin biopsy of the original herpetic lesion area 4 wk 
after its clinical resolution. A similar pattern of CD8+ T cells at the dermal–
epidermal junction was seen in posthealing biopsies of all six subjects. 
Images represented here were from biopsies of subjects P1 (a and c) and 
P3 (b). Bars, 50 μm.600  PERSISTENCE OF HSV-SPECIFIC CD8 AGAINST GENITAL HERPES | Zhu et al.
posthealing biopsies for subjects P2 and P3, respectively, was 
452 cells/mm2 and 355 cells/mm2, an average of four times 
higher than the two 8-wk biopsies from subject P1, who ex-
hibited no detectable viral DNA after healing (104 cells/mm2; 
Fig. 6 b). Subjects P2 and P3 possessed diff  erent HLA types, 
and hence, HSV-specifi  c CD8+ T cells in the 8-wk biopsies 
were detected with diff  erent Qdot multimers, corroborating 
the specifi  city of the in situ detection of HSV-2–specifi  c 
T cells during these episodes of subclinical HSV-2 reactiva-
tion (Fig. 6c-e). The association of CD8 infi  ltration with de-
tection of HSV-2 DNA in the intact epidermis, in the absence 
of clinical symptoms, is most compatible with subclinical 
viral reactivation in which host containment of viral replica-
tion occurred before reactivated virus underwent extensive 
viral replication and disrupted the epithelial surface. These 
fi  ndings suggest that the HSV-2–specifi  c CD8+ T cells at the 
site of genital herpes lesions contribute to local containment 
of viral replication.
D  I  S  C  U  S  S  I  O  N 
One of the major questions in HSV-2 immunobiology has 
been the disparity between animal model data suggesting 
that functional host T cell responses in the ganglia have the 
ability to markedly limit viral reactivation at the ganglion 
level (25, 26) and human clinical studies of HSV-2 re-
activation, which demonstrate that mucosal and genital skin 
shedding of HSV-2 in the immunocompetent person is 
  extremely frequent (27–29). With once daily sampling, HSV-2 
reactivation is seen in 20–60% of days in immunocompetent 
persons. More recent data suggest that high titer reactiva-
tions of HSV-2 lasting only 6–12 h are common (Mark, K., 
personal communication). These human clinical studies in-
dicate that control of mucosal HSV-2 reactivation at the 
ganglion level in humans is incomplete at best. It is likely 
that immune control at both the ganglion and peripheral 
mucosal level is needed for containment of HSV reactiva-
tion. This study was designed to defi  ne whether local host 
control of HSV-2 played an important role in containing 
viral reactivation after lesional clearing. Our data indicate 
that much of the control of HSV-2 reactivation in humans 
appears to be consolidated in the peripheral mucosal im-
mune compartment.
Our study indicates that the peripheral mucosal immune 
response to HSV-2 infection is highly concentrated both 
spatially and functionally. The cytolytic CD8+ T cell infi  l-
tration in genital herpes lesions is very specifi  c to the site of 
infection. The dramatic reduction of CD8+ T cell density 
2 cm outside of the aff  ected skin-lesion area indicates that 
CD8+ T cell infi  ltration to an HSV infection is a very fo-
cused local event. The HSV-2–specifi  c CD8+ T cells we 
detected were highly concentrated in the genital lesion. 
Quantitatively, HSV-2–specifi  c T cells were present at 100 
times higher concentrations in lesional skin than that in cir-
culating blood. Even after lesion resolution, the enrichment 
Figure 5.  Spatial relationship between peripheral nerve endings 
and persisting CD8+ T cells in skin after healing. (a) Distribution of 
superfi  cial nerve networks in dermal sheets. The dermal sheets were 
stained for NCAM (green) and counterstained with DAPI (blue). A projec-
tion of a 70-μm stack is shown from the top edge of the dermis (left). 
Free endings of nerve fi  bers (top) and terminal Schwann cells (bottom) 
are enlarged. (b) Close contact between CD8+ cells and cutaneous nerve 
endings. Biopsy tissue taken 4 wk after healing was double stained for CD8 
(yellow) and NCAM (green). CD8+ cells are in close contact with the basal 
keratinocytes adjacent to free nerve endings at the basement membrane 
(left) and with terminal Schwann cells in the upper dermis (middle). 
A snapshot of a three-dimensional reconstruction (20-μm stack) displays 
spatial closeness between terminal nerve endings (green) and the cell 
with HSV-2 specifi  city (red; right). The tissue was from a biopsy taken 
4 wk after healing and was stained with the A*0101/ASD and B*0702/RPR 
multimers and anti-NCAM antibody. (c) Similar fi  ndings are present in 
biopsy tissue 8 wk after healing. The snapshot shows a reconstructed 
three-dimensional distribution of CD8+ cells and cutaneous nerve endings. 
The image represents 25 μm in z. (d) Biopsy of normal skin of the upper 
arm was double stained for CD8 (yellow) and NCAM (green). Images 
represented were from biopsies of subjects P1 (b–d), P2 (b), and P6 (a). 
Bars, 50 μm.JEM VOL. 204, March 19, 2007  601
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of HSV-2–specifi  c CD8+ T cells persisted in genital skin for 
an extended time period. Our study extended for only 2 mo, 
and local persistence was documented to last at least this 
long. Moreover, the spatial localization of HSV-2–persistent 
CD8+ T cells appears to be of physiological importance. 
Unlike active lesions, where HSV-2–specifi  c CD8+ T cells 
were distributed in all layers of skin to eliminate viral infec-
tion and prevent spreading, HSV-2–specifi  c CD8+ T cells 
that persisted after healing were detected in the upper dermis 
and the dermal–epidermal junction, coincident with sensory 
nerve endings. This physical closeness between persistent 
CD8+ T cells and sensory nerve endings would provide a 
potential mechanism in which the local immune system 
could quickly respond to and eliminate reactivated virus 
  before it undergoes extensive replication. We demonstrated 
four such instances of such containment in two patients, as 
well as the apparent ability of host T cell responses in the peri-
phery to contain viral reactivation before epithelial ulceration 
could occur.
Estimates of the frequency of HSV-specifi  c CD8+ T cells 
in genital skin are likely to be underestimates of their true 
prevalence in our studies. The cocktail of Qdot multimers 
we used was based on only a limited mapping of the breadth 
of the T cell response. As such, it is likely we were assaying 
only a portion of the CD8+ T cell response to the virus. In 
more recent studies using a wider breadth of peptides, we 
have shown that many subjects possess CD8+ T cells specifi  c 
to a wider multitude of HSV proteins than we had available 
here (14). As such, our quantitative assessments are likely 
to be underestimates of the number of HSV-specifi  c CD8+ 
T cells in genital skin.
This study also provides evidence that HSV-specifi  c 
CD8+ T cells play a role in immune protection against 
  clinically symptomatic HSV-2 reactivation in genital skin. 
The biopsies in which we detected HSV DNA in skin tissue, 
without evidence of epithelial cell destruction and in asso-
ciation with increased localized infi  ltration with HSV-2–
  specifi  c CD8+ T cells, suggest that resident HSV-2–specifi  c 
T cells appear to be a critical component of cutaneous 
viral containment. The need to evolve a rapid response to 
viral replication in the desired region is emphasized by a 
  clinical study, which showed that almost 40% of genital 
HSV-2 reactivation in humans were asymptomatic and lasted 
6 h or less (Mark, K., personal communication). These short 
reactivations average from 103 to 104 copies of HSV-2 DNA 
per millimeter in swab specimens, indicating that prompt 
elimination of virus by the host mucosal immune responses 
occurred. Prospective studies investigating the relation-
ship between in vivo persistence of HSV-2–specifi  c T cells 
and the site and timing of clinical and subclinical reactiva-
tion  are needed to defi   ne this association more closely. 
  Although such studies require serial biopsies, patients with 
genital HSV-2 are aff  ected greatly by this infection. The 
Qdot multimers and the in situ staining techniques we 
  describe in this paper provide the tools for such studies to 
be undertaken.
Figure 6.  Subclinical reactivation of HSV-2 in genital skin is asso-
ciated with increased CD8+ T cell infi  ltration. (a–c) Quantitation of 
the HSV-2 genomic DNA (a), total CD8+ T cells (b), and HSV-2–specifi  c 
CD8+ T cells (c) detected in skin biopsies. Each symbol represents one 
subject. HSV-2 DNA copies were quantitated by Taqman real-time PCR 
(see Materials and methods). Biopsies with reappearance of HSV-2 DNA 
after healing are marked with a star. (d and e) Hematoxylin and eosin and 
in situ staining of skin biopsies from subjects P2 (d) and P3 (e), in whom 
HSV-2 DNA was detected at 8 wk after healing. The epithelium is intact 
in both biopsies, and moderate lymphocyte infi  ltration is seen at the 
dermal–epidermal junction and in the dermis (left). In situ staining using 
a cocktail of A*0201 (d, right) and B*0702/RPR (e, right) Qdot multimer 
reveals that HSV-2–specifi  c CD8+ T cells are among the infi  ltrating CD8+ 
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In summary, HSV-2–specifi  c  CD8+ T cells appear to 
play a direct role in viral clearance in vivo. These CD8+ T 
cells migrate very specifi  cally into genital lesions and persist 
preferentially in genital skin in the subepidermal layer con-
tiguous to peripheral nerve endings, suggesting that they play 
a role in the earliest response to viral reactivation. Our studies 
indicate that persisting HSV-2–specifi  c CD8+ T cells func-
tion in immune surveillance and that the peripheral T cell re-
sponse infl  uences the frequency and clinical course of HSV-2 
reactivation in humans.
MATERIALS AND METHODS
Human subjects and specimens. Six subjects (fi  ve female and one male) 
with recurrent genital HSV-2 infection and lesions were recruited into a 
study protocol approved by the University of Washington Institutional Re-
view Board. All subjects were HIV-1/2 seronegative and had a history of 
culture-proven herpes disease. Serial 3-mm punch biopsies were obtained in 
subjects during an episode of symptomatic recurrence from the active lesion 
and at diff  erent stages thereafter (Table I). Lesional punch biopsies were 
taken from the erythematous skin immediately adjacent to a blister. After 
healing, punch biopsies were obtained from the site of the original lesion. In 
addition, 3-mm punch biopsies from an unaff  ected area 2–5 cm away from 
a lesion and/or the arm were also performed. Punch biopsies were divided 
into two halves: one half was snap frozen in optimum cutting temperature 
compound (Tissue-Tek; Sakura Finetek USA, Inc.) and stored at −80°C, 
whereas the other half was cut into three to four pieces and used immedi-
ately for immunofl  uorescence staining. Blood samples were drawn at the 
time of each biopsy.
In some biopsies, the epidermis and dermis were separated as described 
elsewhere (30). In brief, the subcutaneous tissue was removed with surgical 
scissors, and the remaining tissue was placed in cold PBS containing 5 mM 
EDTA and incubated at 4°C overnight. The epidermis was then dissected 
off   the underlying dermis with a stereoscope (KL1500; Carl Zeiss Micro-
Imaging, Inc.).
Synthesis of Qdot multimers. Peptide–MHC complexes (pMHCs) were 
formed in vitro as previously described (31). The HSV-2 peptides used were 
A*0101/ASD (UL46, aa 354–362), A*0201/FLI (UL27, aa 443–451), A*0201/
FLV (UL47, aa 289–298), A*0201/GLA (UL47, aa 551–559), B*0702/RPR 
(UL49, aa 49–57), and B*0702/GPH (UL26, aa 475–483). The CMV peptide 
used was B*0702/NLV (pp65, aa 495–503). Streptavidin-coated Qdot 655 
(Quantum Dot Corporation) was conjugated with a saturating amount of bio-
tinylated pMHC on ice for 15 min and purifi  ed by gel fi  ltration.
Immunofl  uorescence staining. Fresh tissue sections were stained over-
night on ice in a casein solution (Vector Laboratories) with Qdot-conjugated 
MHC–peptide multimers (1:100), mouse anti–human CD8 (1:100; Caltag 
Laboratories), and rabbit anti–HSV-2 (1:500; DakoCytomation). Tissues 
were washed, fi  xed in 4% paraformaldehyde for 20 min at room tempera-
ture, and incubated with donkey anti–mouse Alexa Fluor 488 and donkey 
anti–rabbit Alexa Fluor 594 (1:100; Invitrogen) for 1 h at room temperature. 
After washing and incubating with DAPI (Fluka), tissue sections were 
mounted in Mowiol 40-88 containing 2.5% wt/vol DABCO (Sigma-
  Aldrich). Infi  ltrating CD8+ T cells were enumerated in tissue fi  elds of 460 × 
460 μm in size, including the epidermis and 150–300 μm deep into the der-
mis. For calculating the median number of CD8 and HSV-specifi  c CD8+ 
T cells, at least fi  ve fi  elds were counted for each biopsy. To calculate the per-
centage of HSV-2–specifi  c CD8+ T cells, Qdot multimer and CD8 double-
positive cells were located, and total CD8+ cells along those with HSV 
specifi  city were enumerated in tissue with a volume of 460 × 460 × 20 μm. 
For costaining of CD8+ cells and nerve fi  bers, monoclonal CD8 Alexa Fluor 
647 (1:100; Caltag Laboratories) and NCAM (1:50; Beckman Coulter) were 
used as primary antibodies, and donkey anti–mouse Alexa Fluor 488 was 
used as a secondary antibody.
Confocal microscopy. Confocal microscopy of immunofl  uorescence-
  labeled tissue was performed on a confocal microscope (LSM 510; Carl Zeiss 
MicroImaging, Inc.). For excitation of fl  uorescent dyes, the following laser 
lines were used: Alexa Fluor 488 and FITC, 488 nm; Alexa Fluor 594, 543 
nm; Alexa Fluor 647, 633 nm; and Qdot 655, 458 nm. DAPI was excited in 
two-photon mode with a near-infrared laser (Chameleon; Coherent Inc.) 
tuned at 780 nm. The detection bands for the diff  erent dyes were as follows: 
Alexa Fluor 488 and FITC, 500–550 nm; Alexa Fluor 594, 565–615 nm; Alexa 
Fluor 647, 650–710 nm; Qdot 655, 650–710 nm; and DAPI, 435–485 nm. 
To minimize cross talk between dyes, imaging of multiple labeled samples 
was performed individually for each dye in a sequential mode. To reduce 
image noise, Kalman averaging (generally two to four frames) was used. For 
viewing of Qdot 655, a fi  lter set with a 460-nm short-pass excitation fi  lter, 
a 475-nm beam splitter, and a 635–675-nm band-pass emission fi  lter was 
used (Chroma Technology Corp.). Three-dimensional rendering of con-
focal stacks was performed with Imaris (Bitplane AG) or Volocity (Improvi-
sion) software.
Flow cytometry. 5 × 106 PBMCs were incubated with Qdot 655–conju-
gated pMHC multimers for 15 min at room temperature. CD8-FITC anti-
body (Caltag Laboratories) was added, and cells were incubated for 30 min 
on ice, washed, and fi  xed. Acquisition was performed on a cytometer (LSR 
II; Becton Dickinson), and data were analyzed using CELLQuest software 
(Becton Dickinson). The detection limitation for HSV-2–specifi  c CD8+ 
T cells in PBMCs by fl  ow cytometry was 0.01%.
Real-time quantitative PCR. DNA from skin biopsy samples was ex-
tracted using tissue kits (EZ1; QIAGEN). At least two sets of 60–80-μm 
thick cross-section tissues from each biopsy specimen were treated and fol-
lowed previously described procedures for extraction and testing of HSV 
DNA (32, 33). Subtype-specifi  c typing was performed by real-time PCR 
(34). The HSV DNA copy numbers were normalized to 50,000 cells by 
measuring the β-globin gene copy numbers using 5′-T  G  A  A  G  G  C  T  C  A  T  G-
G  C  A  A  G  A  A  A  -3′ and 5′-G  C  T  C  A  C  T  C  A  G  T  G  T  G  G  C  A  A  A  G  G  -3′ as primers 
and 5′-T  C  C  A  G  G  T  G  A  G  C  C  A  G  G  C  C  A  T  C  A  C  T  A  -3′ as a probe. The detec-
tion limitation of the assay was one copy per 50,000 cells.
Online supplemental material. Video 1 shows detection of CD8+ cells 
in a genital herpes lesion. Video 2 provides a 180° view showing direct 
interaction between CD8+ T cells and HSV-2–infected keratinocytes. 
Video 3 depicts the surface distribution of CD8 and TCR molecules on 
an HSV-2–specifi  c CD8+ T cell. Video 4 shows the distribution of CD8+ 
and HSV-specifi  c T cells in a newly healed genital herpes lesion. Video 5 
provides a 360° display of persistent HSV-specifi  c CD8+ T cells in healed 
genital skin. Video 6 presents a 360° display of persistent HSV-specifi  c 
CD8+ T cells contiguous to cutaneous sensory nerve endings in healed 
genital skin. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20061792/DC1.
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